UK: Brexit: Life Sciences Implications

Last Updated: 21 September 2016
Article by Sally Shorthose and Toby Sears

On 23 June 2016, the UK public voted to leave the EU. Under Article 50 of the Lisbon Treaty, the EU Treaties shall cease to apply to the UK:

  • from the date of entry into force of the withdrawal agreement that the UK negotiates with the Union, acting through the Council; or
  • two years after the UK has notified the European Council of its intention to withdraw, unless the European Council, in agreement with the UK, unanimously decides to extend this period.

Therefore, in practice the British exit ("Brexit") date is most unlikely be before July 2018, or January 2019 given the recent indication by the Prime Minister that notification will not be given before 2017.

This briefing note advises on the immediate considerations and anticipates how Brexit will impact the Life Sciences sector. This article is part of our Brexit series and Life Sciences businesses will be affected by all of the implications identified throughout this series and, in particular, our note on the English Intellectual Property law implications of Brexit.

What is the immediate effect of the Brexit Vote

As the UK will remain within the EU for at least the next 2 years, in the short term the answer is that it should be "business as usual" for the Life Sciences sector in the UK.

The decision as to which model will be adopted by the UK and the EU post-Brexit will determine how the Life Sciences sector is truly affected.

If the UK remains in the European Economic Area (EEA), then the effects are likely to be minimal on the sector. This is because the UK would keep access to many of the benefits of the EU system, such as the centralised procedure for marketing authorisations, the EU portal for clinical trials and the Pharmacovigilance database. Similarly, if the UK joins the European Free Trade Association (EFTA) and negotiates sector specific access to the single market, then, depending on the exact nature of the relationship, effects may again be limited. If, however, the UK choses to move further away from the EU, or cannot agree the terms of a continued close association with the EU, then the effects may be more severe.

It is therefore uncertain what the full ramifications of Brexit are going to be and we therefore suggest the best policy at this time is to be prepared by keeping up to date as the process develops.

What future issues may the Life Sciences sector face following Brexit

Legislation

The Life Sciences sector is one of the most highly regulated and globally harmonised industry sectors especially in terms of the development of pharmaceutical products. A large amount of the regulation originates from membership of the EU in the form of Directives or Regulations. In the case of Directives (e.g. Directive 2001/83/EC governing medicinal products) these have been implemented into national law and will therefore remain in place (subject to amendment). Regulations, in contrast, are directly applicable in the UK without the need for national implementation and therefore when the UK leaves the EU, the Regulations will no longer apply.

There is no reason why the UK Government could not enact these equivalent rules into UK law (in some cases this will not be required if we are part of the EEA/EFTA). If, however, the UK Government decide to no longer align themselves with European law the administrative burden of life sciences companies could increase significantly because regulatory requirements, for example clinical trial authorisations and marketing authorisation applications, may need to be obtained under a new and different legal framework. However, realistically even under a "Swiss type", hybrid situation, the Regulations and standards are unlikely to change substantially as the UK will wish to continue to facilitate free trade both within Europe and globally and would not wish to build artificial barriers.

Clinical Trials

The new Clinical Trials Regulation 536/2014 was adopted on 16 June 2014 but has not yet been implemented (it is expected to be in force by October 2018). The new Regulation provides for a single application for clinical trials across the EU (through a single portal) with an associated EU wide database. This Regulation will apply to clinical trials for medicinal products and, if it comes into force before Brexit, the UK will be bound by it until its departure. However, following Brexit the Regulation will not automatically continue to apply.

If the UK adopts significantly different national legislation to Regulation 536/2014, this is likely to make the clinical trials procedure increasingly complex with greater administrative burden and cost for companies wishing to conduct multi-centre clinical trials in the EU and the UK. In particular, UK companies will not have access to the single portal for applications for clinical trials, or if they do there may be a substantial fee, and separate centralised and national clinical trial authorisation procedures will need to be followed. Furthermore, companies will have to ensure that sponsors of a clinical trial have legal representation established in the EU but, for large life science companies at least, this is unlikely to pose a significant administrative issue.

Additional questions will also arise in relation to data protection (in particular clinical trial data and personal data) currently falling under the EU Data Protection Directive which should be borne in mind but is beyond the scope of this article. More detailed advice may be found here.

Marketing Authorisations

The majority of Marketing Authorisations are applied for under the decentralised procedure (national) or the centralised procedure (EU wide); each application process is determined by Directive 2001/83/EC. Following Brexit (if the UK is outside the EEA) a system for independent Marketing Authorisation approval will need to be adopted in the UK.

Marketing Authorisations granted by the UK will be unaffected and it is likely that marketing authorisations granted in the EU under the centralised procedure prior to the exit will be recognised by the UK. However, centralised marketing authorisations covering the EU held by UK companies will have to be transferred to companies established in EU countries unless mutual recognition agreements are put in place.

If nothing else having to apply for marketing authorisation in the UK as well as the EU will add to the regulatory burden, increase barriers to the market and costs for the life sciences industry. As mentioned below, the Medicines & Healthcare Products Regulatory Agency (MHRA) will find that its workload increases commensurately as the centralised procedures are dismantled.

Quality Assurance and Product Safety

It is likely that quality assurance procedures will need to be maintained in the UK in line with current EU good manufacturing practices in order to ensure products can be sold in the EU. This requires all EEA located manufacturers and importers of medicines to hold a manufacturing authorisation. Even if the UK is not part of the EEA after Brexit, UK manufacturers could continue exporting medicines to the EU and vice versa if equivalence is maintained in the UK/EU regulatory frameworks. This is likely to be the case for the UK in order to facilitate importation through mutual recognition agreements with the EU and other trading nations. However, the cost of importing into the EU may increase if the EU imposes additional requirements and inspections on non-EU imports.

Furthermore, uniform product safety laws, as applied currently across the EU (e.g. the General Product Safety Directive (2001/95/EC)), are likely to continue post Brexit in common with those of the EU and globally so as to maintain the competitiveness of UK goods and suppliers.

R&D and Funding

The EU currently provides funding and coordinates research collaborations through funding programmes such as the Innovative Medicines Initiative and Horizon 2020 (a 7-year programme with €80 billion to provide public/private sector collaborations and encourage innovation). If the UK is not part of the EEA following Brexit, access to this funding will be lost to UK-based companies without research facilities in other EU countries. It is also unclear whether the UK Government will supplement the lost funding and seek to establish bilateral agreements with other nations in order to access other funding/collaboration options.

Pharmacovigilance

The EU pharmacovigilance system is coordinated by the European Medicines Agency (EMA) which, as discussed below, may need to be relocated following Brexit. UK companies will therefore need to revise their pharmacovigilance reporting system as a single person cannot perform the pharmacovigilance function for the EU and UK as the appropriately qualified person should reside and operate in the EU.

Regulatory Authorities

The EMA is based in London and currently employees 890 people. When discussing the implications of Brexit the EMA website that "Its implications for the Agency's location and operations depend on the future relationship between the UK and the EU, which is unknown at present". It is understood that Sweden, Spain, Denmark and Italy have already expressed interest in providing the EMA a new home.

Should the UK not become part of the EEA, the EMA and MHRA will be significantly affected. The MHRA has stated their need to increase employee numbers to carry out the regulatory work, which would have previously been handled by EMA. In addition, where previously the EMA cooperated with the ICH, FDA, Japanese PMDA and other competent authorities, the MHRA will now need to negotiate its own cooperation agreements to replace those agreed by the EMA.

There will be further, hopefully more minor, impacts made to other UK agencies (e.g. NICE) that are beyond the scope of this article.

Parallel Importation

If the UK remains part of the EEA, then EU exhaustion of rights continues to apply and the free movement of goods will be preserved. However, outside the EEA EU exhaustion of rights rules will cease and it is unclear what the UK government will replace them with. If the UK leaves the single market, pharmaceutical companies may be able to assert their IP rights to stop parallel importation into the UK (in addition to other existing defenses) which may be seen as a benefit of Brexit by the life sciences sector.

Specific Impacts on Intellectual Property Rights

Unitary Patent System

The new EU patent regime was due to begin at the end of 2017 providing patentees with the option to apply for a single, pan-EU Unitary Patent (UP) covering most of EU, accompanied by the Unified Patent Court (UPC) to hear and determine patent disputes on a EU wide basis. The UPC currently requires ratification by the UK as one of several countries needed to bring the UPC into force. The UK may still take this step before the UK leaves the EU. However, if this does not happen, once the UK has left, the UPC Agreement will enter into force as soon as it has been ratified by 13 Member States, including Germany, France and Italy, instead of the UK. A deadlock may exist until the UK has actually left the EU, which might take several years and negotiating an additional protocol would take time.

However, it is possible that even after the UK leaves the EU it may be able to keep its membership of the Unitary Patent System if the UK becomes part of the EEA as such an agreement might include amendments to the UPC Agreement that would allow the UK to remain a Contracting Member State. However, because of Article 20 of the Treaty on European Union, the UP cannot cover the UK following Brexit, but the UPC might still have jurisdiction for the UK with regard to traditional European patents (dependent on amendments made to the UPC Agreement). Even if the UK maintains some form of link to the Unitary Patent System the UK is likely to be viewed as a less attractive destination for life sciences companies looking to acquire pan-European patent protection.

In addition the planned Unitary Patent Court Central Division which was to be based in London will have to be relocated (likely candidates would be Milan and The Hague) following Brexit.

SPC's

The additional protection afforded to patentees by Supplementary Protection Certificates (SPCs) introduced via two EU Regulations will no longer apply to the UK following Brexit. These extensions to patent protection of up to 5 years are very valuable and similar extensions are available in many countries around the world (e.g. the US and Japan). It is therefore likely that equivalent regulations will be enacted by the UK Government but it is unclear what the nature of these will be and what fate awaits existing SPCs.

Trademarks and Registered Community designs

When the UK does leave the EU, European Union trademarks (EUTMs) and Registered Community designs (RCDs) will cease to be in force. However, it is likely there will be some mechanism for these to be converted into UK rights. As a result, owners of existing EU-wide registered rights should not without further advice immediately react by filing new UK applications, as it is likely that the filing dates of their existing rights for UK will be maintained in some way. However, it is unclear how this conversion mechanism will operate, or whether there will be a fee payable to the UK IPO.

In general, for trademark and design owners filing new applications now, there is a choice: apply EU-wide and hope to be able "convert" those rights into UK rights later; or file both UK and EU-wide applications now, to avoid having to rely on any conversion mechanism. Which option to take is likely to depend on the particular circumstances.

www.twobirds.com

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.